C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally ...
The association of increased C4 with schizophrenia (Figs 4 and 5), the presence of C4 at synapses (Fig. 6b, d), the involvement of other complement proteins in synapse elimination 29, 30, 31, and ...
Use left and right arrow keys to scroll through schedule ...
Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results